FAME II Trial

Share

chevron_left Newsroom

Feb. 03, 2020

PCI in patients with FFR ≤ 0.80 reduced clinical events by 66% compared to medical therapy alone at 1 year.

The FAME II Trial randomized stable CAD patients with FFR ≤ 0.80 to PCI + medical therapy or medical therapy alone. Enrollment was halted early after 1,220 patients because of a significant between-group difference in the events, driven by a lower rate of urgent revascularization in the PCI group than in the medical therapy group.

Recent Articles

Learn how the CathWorks FFRangio System can impact your practice.

*Required

expand_lessBack to top of page

We use cookies to enhance your experience. By continuing to visit this site, you agree to our use of cookies. Terms and Conditions

Accept